Memorial Sloan Kettering Joins Phase 1/2 Trial of IMUNON's IMNN-001 Plus Bevacizumab for Advanced Ovarian Cancer

A clinical-stage biopharmaceutical company, IMUNON, Inc., is conducting a Phase 1/2 clinical trial to assess the efficacy of a combined treatment for advanced ovarian cancer. The trial involves the use of IMUNON’s IMNN-001, a DNA-based immunotherapy, alongside bevacizumab, in patients with this condition. The collaboration includes Memorial Sloan Kettering Cancer Center and MD Anderson Cancer Center, aiming to enroll 50 patients with Stage III/IV ovarian cancer. The primary goal of the study is to detect minimal residual disease through second-look laparoscopy, with progression-free survival as a secondary endpoint. The trial is expected to yield initial data within a year of completion and final data after approximately three years. It also encompasses translational research to understand the genetic and immunological characteristics of undetectable ovarian cancer minimal residual disease. The study is led by Dr. Amir Jazaeri and involves the Koch Institute for Integrative Cancer Research at MIT for further analysis.

IMUNON’s IMNN-001 is an interleukin-12 (IL-12) immunotherapy delivered via a nanoparticle system, which has shown positive safety and Phase 1 results when used as a monotherapy or in combination with chemotherapy drugs. The company is also working on a COVID-19 vaccine and treatments for other diseases, leveraging its plasmid DNA technology to develop innovative therapies.

Epithelial ovarian cancer is the fifth leading cause of cancer-related deaths among women in the U.S., with most cases diagnosed at advanced stages. The survival rates for these stages are low, highlighting the urgent need for effective treatments that can reduce recurrence and improve survival rates. IMUNON’s approach to immunotherapy could potentially transform the treatment landscape for this aggressive form of cancer.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!